Park Hotels & Resorts Inc. Common Stock vs Repligen Corporation Common Stock — how do they compare? Park Hotels & Resorts Inc. Common Stock trades at $15.06 (market cap $3.14B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Repligen Corporation Common Stock is far larger — about 3.5× Park Hotels & Resorts Inc. Common Stock's market cap, and Park Hotels & Resorts Inc. Common Stock pays a 6.41% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Park Hotels & Resorts Inc. Common Stock for 0 Days and Repligen Corporation Common Stock for 0 Days on average.
| PK | RGEN | |
|---|---|---|
Market Cap | $3.14B | $11.14B |
Volume | 3,553,985 | 1,259,263 |
Sector | Real Estate | Health |
52-Week High | $16.17 | $194.57 |
52-Week Low | $9.84 | $102.87 |
Typical Hold Time | 0 Days | 0 Days |
Enterprise Value | $6.98B | $11.02B |
Dividend Yield | 6.41% | — |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Park Hotels & Resorts Inc. is a US lodging REIT, spun off from Hilton Worldwide in 2017, that owns a portfolio of premium-branded hotels and resorts in major urban, resort, and convention markets.
Read more on PK →Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →